Top Markets
#1 ADO Protocol ADO Protocol +324.24%
#2 Islamic Coin Islamic Coin +155.41%
#3 GoPlus Security GoPlus Security +59.57%
#4 Starpower Starpower +34.32%
#5 Verus Coin Verus Coin +33.01%
#6 GAIB AID GAIB AID +24.67%
#7 Casper Network Casper Network +14.40%
#8 o1.exchange o1.exchange +12.87%
#9 Status Status +12.12%
#10 Lumia Lumia +10.89%
Coin of the day
ADO Protocol ADO Protocol
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc.

CNSP
Rang in Aktien #33273
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily... CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Aktienkurs
$5.47
Zuletzt synchronisiert: 2026-08-14
Marktkapitalisierung
$7.99M
Veränderung (1 Tag)
6.21%
Veränderung (1 Jahr)
7.47%
Land
US
Handel CNS Pharmaceuticals, Inc. (CNSP)

Kategorie

Healthcare
P/S-Verhältnis für CNS Pharmaceuticals, Inc. (CNSP)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von CNS Pharmaceuticals, Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für CNS Pharmaceuticals, Inc. von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.74 -
BE